E. Santagostino

发表

Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

C. Hermans, V. Jiménez‐Yuste, G. Auerswald, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study

C. Königs, E. Santagostino, H. M. van den Berg, 2020, Thrombosis and Haemostasis.

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

J. Blatny, E. Santagostino, M. Recht, 2020, Blood advances.

Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A.

C. Königs, R. Ljung, E. Santagostino, 2019, Blood.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

C. Hermans, E. Santagostino, C. Kessler, 2019, Blood reviews.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study

J. Oldenburg, E. Santagostino, M. Recht, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

J. Oldenburg, R. Ljung, E. Santagostino, 2017, Thrombosis and Haemostasis.

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

G. Auerswald, R. Ljung, E. Santagostino, 2015, Thrombosis and Haemostasis.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

V. Ramanan, P. Mannucci, F. Rosendaal, 2016, The New England journal of medicine.

Switching treatments in haemophilia: is there a risk of inhibitor development?

V. Jiménez‐Yuste, G. Auerswald, G. Benson, 2014, European journal of haematology.

nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene (

J. Astermark, R. Keenan, J. Oldenburg, 2014 .

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity

A. Iorio, J. Astermark, T. Lambert, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors – genetic and environmental factors

E. Santagostino, K. Fijnvandraat, D. Lillicrap, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

GENERAL INTRODUCTION AND OUTLINE OF THE THESIS

J. Astermark, R. Keenan, J. Oldenburg, 2012 .

THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

J. Astermark, R. Keenan, J. Oldenburg, 2013 .

Factor VIII products and inhibitor development in severe hemophilia A.

R. Ljung, E. Santagostino, J. G. van der Bom, 2013, The New England journal of medicine.

Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression

A. Iorio, P. Mannucci, M. Marcucci, 2013, Journal of thrombosis and haemostasis : JTH.

Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies

P. Mannucci, E. Santagostino, M. Franchini, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

How we choose factor VIII to treat hemophilia.

P. Mannucci, E. Santagostino, M. Mancuso, 2012, Blood.

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A

P. Mannucci, E. Santagostino, P. Mannucci, 2012, Journal of thrombosis and haemostasis : JTH.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

A. Iorio, M. Marcucci, E. Santagostino, 2010, Journal of thrombosis and haemostasis : JTH.

Venous access in haemophilic children: choice and management

E. Santagostino, M. Mancuso, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia care in children – benefits of early prophylaxis for inhibitor prevention

G. Auerswald, E. Santagostino, M. Mancuso, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs

V. Jiménez‐Yuste, G. Benson, T. Lambert, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high‐responding inhibitors

M. Margaglione, P. Mannucci, E. Grandone, 2009, Journal of thrombosis and haemostasis : JTH.

Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters

P. Mannucci, E. Santagostino, M. Mancuso, 2008, British journal of haematology.

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice

E. Santagostino, K. Fischer, J. G. van der Bom, 2008, Journal of thrombosis and haemostasis : JTH.

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers)

P. Mannucci, E. Santagostino, F. Peyvandi, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.

E. Santagostino, P. Mannucci, M. Mancuso, 2006, Haematologica.

Inhibitor development, immune tolerance and prophylaxis in haemophilia A – the need for an evidence‐based approach

P. Mannucci, E. Santagostino, V. Blanchette, 2006, Haemophilia.

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain‐deleted recombinant factor VIII

M. Morfini, E. Santagostino, P. Mannucci, 2004, British journal of haematology.

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A

P. Giangrande, G. Auerswald, M. Morfini, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Integrated postural analysis in children with haemophilia

E. Santagostino, P. Mannucci, M. Mancuso, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Rationale for individualizing haemophilia care

G. Auerswald, G. Benson, T. Lambert, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

E. Santagostino, M. Mancuso, A. Rocino, 2006, Journal of thrombosis and haemostasis : JTH.

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia

G. Pravettoni, A. Nobili, E. Santagostino, 2015, Clinical interventions in aging.

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2016, Thrombosis research.

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open‐label phase 3 trial

E. Santagostino, M. Carcao, S. Rangarajan, 2016, Journal of thrombosis and haemostasis : JTH.

Hepatitis C in haemophilia: lights and shadows

M. Colombo, E. Santagostino, F. De Filippi, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

A. Duffy, C. Hermans, V. Jiménez‐Yuste, 2018, European journal of haematology.

The importance of inhibitor eradication in clinically complicated hemophilia A patients

J. Oldenburg, E. Santagostino, G. Young, 2018, Expert review of hematology.

A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies

E. Santagostino, M. Carcao, P. Mannucci, 2018, Expert review of hematology.

Joint protection in haemophilia

Christine A. Lee, L. Valentino, V. Jiménez‐Yuste, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Comparison of thrombin generation for paired‐platelet‐rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor‐VIII inhibitor bypassing agents

E. Santagostino, M. Mancuso, A. Tripodi, 2012, Journal of thrombosis and haemostasis : JTH.

Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe haemophiliacs: comment

E. Santagostino, A. Tripodi, V. Chantarangkul, 2015, Journal of thrombosis and haemostasis : JTH.

Usefulness of bone microarchitectural and geometric DXA‐derived parameters in haemophilic patients

E. Santagostino, M. Mancuso, E. Boccalandro, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A

E. Santagostino, M. Mancuso, F. Peyvandi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents

E. Santagostino, M. Mancuso, F. Peyvandi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients

E. Santagostino, K. Hamulýak, P. Kamphuisen, 2013, British journal of haematology.

Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile

M. Clerici, P. Mannucci, E. Santagostino, 2010, Journal of thrombosis and haemostasis : JTH.

Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection.

G. Pantaleo, A. Lazzarin, H. Sheppard, 2000, The Journal of infectious diseases.

Shorter Survival of SDF 1-3 ′ A / 3 ′ A Homozygotes Linked to CD 4 + T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection

G. Pantaleo, A. Lazzarin, H. Sheppard, 2022 .

Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations.

E. Santagostino, P. Mannucci, S. Duga, 2003, Blood.

How I treat age-related morbidities in elderly persons with hemophilia.

P. Mannucci, E. Santagostino, R. Schutgens, 2009, Blood.

Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.

A. Iorio, M. Morfini, E. Santagostino, 2013, Blood transfusion = Trasfusione del sangue.

Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study

T. Lambert, E. Santagostino, H. Chambost, 2020, Thrombosis and Haemostasis.

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

E. Santagostino, A. Neff, A. Tosetto, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

E. Santagostino, C. Négrier, R. Klamroth, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

J. Oldenburg, E. Santagostino, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

P. Giangrande, J. Oldenburg, E. Santagostino, 2016, Thrombosis and Haemostasis.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Bioequivalence between two serum‐free recombinant factor VIII preparations (N8 and ADVATE®) – an open‐label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

M. Morfini, E. Santagostino, D. Viuff, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates

A. Zanetti, E. Santagostino, A. Gringeri, 1994, The Lancet.

Daclatasvir/peginterferon lambda‐1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa‐2a/ribavirin

S. Pol, E. Santagostino, H. Reesink, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Beyond patient benefit: clinical development in hemophilia

G. Auerswald, G. Benson, T. Lambert, 2012, Hematology.

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A

A. Iorio, M. Marcucci, E. Santagostino, 2015, Thrombosis and Haemostasis.

Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

M. Morfini, E. Santagostino, M. Franchini, 2014, Blood transfusion = Trasfusione del sangue.

Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors

M. Margaglione, E. Santagostino, P. Mannucci, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Relationship between Factor VII Activity and Clinical Efficacy of Recombinant Factor VIIa Given by Continuous Infusion to Patients with Factor VIII Inhibitors

M. Morfini, E. Santagostino, A. Rocino, 2001, Thrombosis and Haemostasis.

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

D. Fuchs, L. Boon, A. Iorio, 2015, The Journal of clinical investigation.

Liver histology of an afibrinogenemic patient with the Bβ‐L353R mutation showing no evidence of hepatic endoplasmic reticulum storage disease (ERSD); comparative study in COS‐1 cells of the intracellular processing of the Bβ‐L353R fibrinogen vs. the ERSD‐associated γ‐G284R mutant

E. Santagostino, G. Coggi, S. Duga, 2005, Journal of thrombosis and haemostasis : JTH.

Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs.

E. Santagostino, P. Mannucci, S. Duga, 2001, Blood.

High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C.

E. Santagostino, A. Gringeri, M. Muça-Perja, 1998, Blood.

High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C

E. Santagostino, P. Mannucci, A. Gringeri, 1998 .

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

E. Santagostino, S. Lethagen, S. Aballéa, 2020, Journal of blood medicine.

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

L. Alberio, Songkai Yan, E. Santagostino, 2019, Journal of medical economics.

Safety Profile of Porcine Factor VIII and Its Use as Hospital and Home-Therapy for Patients with Haemophilia-A and Inhibitors: the Results of An International Survey

P. Mannucci, E. Santagostino, M. Laffan, 1996, Thrombosis and Haemostasis.

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

M. Morfini, E. Santagostino, M. Franchini, 2015, Blood transfusion = Trasfusione del sangue.

Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study

P. Mannucci, E. Santagostino, A. Tagliaferri, 2005, British journal of haematology.

More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance

E. Santagostino, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Difficult clinical challenges in haemophilia: international experiential perspectives

P. Giangrande, E. Santagostino, C. Kessler, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement

E. Santagostino, M. Franchini, P. Mannucci, 2016, Seminars in Thrombosis & Hemostasis.

Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A

P. Mannucci, E. Santagostino, A. Tosetto, 2009, Journal of thrombosis and haemostasis : JTH.

Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.

E. Santagostino, F. Peyvandi, A. Tripodi, 2019, Thrombosis research.

New predictive approaches for ITI treatment

C. Königs, E. Santagostino, C. Königs, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Management of bleeding disorders: basic science

E. Santagostino, S. Grancha, F. Ofosu, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection.

L. Chieco‐Bianchi, V. Coppola, E. Santagostino, 1999, AIDS research and human retroviruses.

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

E. Santagostino, A. Regnault, S. Seremetis, 2015 .

Increased Thrombin Generation in Severe Hemophiliacs with Mild Clinical Phenotype

P. Mannucci, E. Santagostino, M. Mancuso, 2008 .

Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches

E. Santagostino, A. Coppola, M. D. Di Minno, 2010, British journal of haematology.

Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.

P. Giangrande, E. Santagostino, M. Ozelo, 2015, Blood reviews.

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?

Christine A. Lee, V. Jiménez‐Yuste, M. Morfini, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

M. Morfini, E. Santagostino, Mark P Smith, 2003, British journal of haematology.

Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients.

E. Santagostino, P. Mannucci, S. Duga, 2004, Haematologica.

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

E. Santagostino, A. Gringeri, P. Mannucci, 1999, British journal of haematology.

Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients

J. M. Lipton, E. Santagostino, A. Catania, 1998, Peptides.

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

P. Mannucci, E. Santagostino, P. Mannucci, 2003, British journal of haematology.

Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein.

E. Santagostino, P. Mannucci, S. Duga, 2003, Blood.

Tat toxoid as a component of a preventive vaccine in seronegative subjects.

A. Burny, E. Santagostino, J. Zagury, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrate

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Real‐world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry

E. Santagostino, H. Chambost, M. Laffan, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Peri-operative and Post-operative Management of Hemophiliac Patients without Inhibitors

E. Santagostino, M. Mancuso, 2008 .

Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody.

E. Santagostino, P. Mannucci, A. Gringeri, 1991, Haemostasis.

Hemophilia A and Hemophilia B: Different Types of Diseases?

E. Santagostino, M. R. Fasulo, M. Fasulo, 2013, Seminars in Thrombosis & Hemostasis.

Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery

P. Mannucci, E. Santagostino, K. Bauer, 1994, Thrombosis and Haemostasis.

A novel two base pair deletion in the factor V gene associated with severe factor V deficiency.

E. Santagostino, P. Mannucci, S. Duga, 2000 .

A novel two base pair deletion in the factor V gene associated with severe factor V deficiency

P. Mannucci, E. Santagostino, P. Mannucci, 2000, British journal of haematology.

Intramuscular anti‐D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura

P. Mannucci, E. Santagostino, A. Gringeri, 1992, British journal of haematology.

Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A

E. Santagostino, C. T. Ammollo, F. Semeraro, 2020, Journal of thrombosis and haemostasis : JTH.

Accelerated schedule of hepatitis B vaccination in patients with hemophilia

E. Santagostino, P. Mannucci, A. Rocino, 1993, Journal of medical virology.

Long‐term treatment with zidovudine in patients with human immunodeficiency virus (HIV)‐associated thrombocytopenia: Modes of response and correlation with markers of HIV replication

A. Lazzarin, P. Cinque, E. Santagostino, 1993, European journal of haematology.

Clinical issues in inhibitors

J. Astermark, E. Santagostino, W. Keith Hoots, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemostatic effect of bypassing agents

J. Astermark, E. Santagostino, W. Keith Hoots, 2010 .

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid.

E. Santagostino, J. Zagury, A. Gringeri, 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

J. Oldenburg, E. Santagostino, M. Carcao, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate

P. Mannucci, E. Santagostino, K. Bauer, 1991, British journal of haematology.

PCR analysis of HIV‐1 sequences and differential immunological features in seronegative and seropositive haemophiliacs

C. Peschle, G. Mariani, U. Testa, 1992, British journal of haematology.

Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia.

Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

M. Morfini, E. Santagostino, M. Franchini, 2013, Seminars in Thrombosis & Hemostasis.

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

E. Santagostino, K. Fischer, G. Kenet, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Switching patients in the age of long-acting recombinant products?

A. Iorio, E. Santagostino, C. Négrier, 2019, Expert review of hematology.

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

W. Blattner, A. Burny, E. Santagostino, 1998, Journal of human virology.

Non-Compartment and Compartmental Pharmacokinetics, Efficacy, and Safety of Kedrion FIX concentrate.

E. Santagostino, S. Aksu, G. Castaman, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies

P. Mannucci, E. Santagostino, M. Franchini, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors to Factor VIII in a Family with Mild Hemophilia: Molecular Characterization and Response to Factor VIII and Desmopressin

P. Mannucci, E. Santagostino, A. Gringeri, 1995, Thrombosis and Haemostasis.

State of Care for Hemophilia in Pediatric Patients

E. Santagostino, P. Mannucci, A. Gringeri, 2002, Paediatric drugs.

Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.

E. Santagostino, C. Hay, C. Kasper, 1993, Seminars in hematology.

Factors influencing the long‐term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution

P. Mannucci, E. Santagostino, M. Mancuso, 2009, British journal of haematology.

European retrospective study of real‐life haemophilia treatment

J. Oldenburg, C. Hermans, G. Dolan, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers.

P. Pontisso, M. Morfini, E. Santagostino, 1997, Blood.

Total joint replacement in patients with inhibitors

E. Santagostino, G. Pasta, L. Solimeno, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

R. Ljung, E. Santagostino, V. Blanchette, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

J. Oldenburg, E. Santagostino, C. Kessler, 2017, The New England journal of medicine.

Joint disease, the hallmark of haemophilia: what issues and challenges remain despite the development of effective therapies?

V. Jiménez‐Yuste, G. Auerswald, G. Benson, 2014, Thrombosis research.

Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)

M. Morfini, E. Santagostino, A. Tagliafico, 2013, Thrombosis and Haemostasis.

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

E. Santagostino, M. Mancuso, I. Pabinger, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

International workshop on immune tolerance induction: consensus recommendations 1

E. Santagostino, S. Pipe, G. Rivard, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

WFH Guidelines for the Management of Hemophilia, 3rd edition

E. Santagostino, M. Carcao, B. Feldman, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies

C. Hermans, E. Santagostino, S. Apte, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels

R. Ljung, E. Santagostino, M. Carcao, 2016, Thrombosis and Haemostasis.

Optimising musculoskeletal care for patients with haemophilia

E. Santagostino, M. Carcao, J. Mahlangu, 2015, European journal of haematology.

Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?

C. Hermans, G. Dolan, E. Santagostino, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

M. Morfini, E. Santagostino, C. Négrier, 2012, Blood.

Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications

E. Santagostino, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa

A. Iorio, E. Santagostino, A. Regnault, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

E. Santagostino, J. Mahlangu, S. Lalezari, 2020, European journal of haematology.

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

P. Mannucci, E. Santagostino, M. Franchini, 2009, Journal of thrombosis and haemostasis : JTH.

The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding

Flora Peyvandi, H. Hemker, R. al Dieri, 2002, Thrombosis and Haemostasis.

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

A. Savic, E. Santagostino, Y. Amit, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.

E. Santagostino, H. Ng, S. Lalezari, 2019, Thrombosis research.

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.

A. Iorio, P. Mannucci, M. Morfini, 2009, Blood.

PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2012, Thrombosis Research.

When should prophylaxis therapy in inhibitor patients be considered?

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE)

M. Morfini, E. Santagostino, M. Franchini, 2018, Seminars in Thrombosis and Hemostasis.

Principles of care for acquired hemophilia

C. Hermans, V. Jiménez‐Yuste, G. Benson, 2021, European journal of haematology.

Involvement of the IgE‐basophil system and mild complement activation in haemophilia B with anti‐factor IX neutralizing antibodies and anaphylaxis

E. Santagostino, P. Mannucci, M. Mancuso, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

J. Oldenburg, E. Santagostino, B. Konkle, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

The need for speed in the management of haemophilia patients with inhibitors

G. Benson, R. Ljung, M. Morfini, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

A. Duffy, C. Hermans, V. Jiménez‐Yuste, 2017, Blood transfusion = Trasfusione del sangue.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study

G. Spotts, J. Oldenburg, C. Hermans, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Defining extended half‐life rFVIII—A critical review of the evidence

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Miguel Ángel Martínez, P. Mannucci, E. Santagostino, 2015 .

A Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients

Silvia Riva, Gabriella Pravettoni, Caspar Krampe, 2015, Front. Hum. Neurosci..

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

E. Santagostino, M. Ozelo, V. Vdovin, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Polypharmacy in older adults with severe haemophilia

A. Nobili, E. Santagostino, P. Mannucci, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Practical aspects of extended half-life products for the treatment of haemophilia

C. Hermans, V. Jiménez‐Yuste, G. Benson, 2018, Therapeutic advances in hematology.

Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

A. Iorio, E. Santagostino, A. Rocino, 2011, Blood transfusion = Trasfusione del sangue.

GlycoPEGylated recombinant factor IX for hemophilia B in context

E. Santagostino, M. Mancuso, 2018, Drug design, development and therapy.

Population pharmacokinetics of a new long‐acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B

M. Morfini, E. Santagostino, D. Bensen-Kennedy, 2016, Journal of thrombosis and haemostasis : JTH.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

E. Santagostino, L. Boggio, C. Négrier, 2016, Blood.

Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2019, Haemophilia.

A new recombinant factor VIII: from genetics to clinical use

E. Santagostino, 2014, Drug design, development and therapy.

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A

M. Morfini, E. Santagostino, G. Di Minno, 2019, Patient preference and adherence.

Work Productivity and Activity Impairment Questionnaire ( WPAI ) + Classroom Impairment Questions ( CIQ ) : Hemophilia Specific ( HS ) :

M. Morfini, E. Santagostino, E. Baldacci, 2019 .

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

E. Santagostino, W. Seifert, M. Mancuso, 2020, Journal of thrombosis and haemostasis : JTH.

Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Santagostino, A. Lienhart, C. Négrier, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

J. Oldenburg, E. Santagostino, C. Kessler, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

W. Ageno, G. Lippi, E. Santagostino, 2019, Blood transfusion = Trasfusione del sangue.

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice

J. Oldenburg, E. Santagostino, L. Boggio, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B

E. Santagostino, M. Carcao, M. Taki, 2020, Thrombosis and Haemostasis.

Insight into health‐related quality of life of young children with haemophilia B treated with long‐acting nonacog beta pegol recombinant factor IX

E. Santagostino, V. Blanchette, N. Young, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children

T. Lambert, E. Santagostino, H. Chambost, 2016, Thrombosis and Haemostasis.

Prevention of arthropathy in haemophilia: prophylaxis

E. Santagostino, M. Mancuso, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up

E. Santagostino, M. Mancuso, L. Berardinelli, 2009, Haematologica.

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

V. Jiménez‐Yuste, E. Santagostino, R. Klamroth, 2020, Haematologica.

Models for institutional and professional accreditation of haemophilia centres in Italy

M. Morfini, E. Santagostino, P. Mannucci, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

2 coagulation disorders factor VIII and IX deficiency: an index of different clinical severity of the Comparison of the rates of joint arthroplasty in patients with severe

A. Iorio, P. Mannucci, M. Morfini, 2013 .

First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

E. Santagostino, A. Neff, C. Négrier, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients.

Flora Peyvandi, Kevin Blighe, E. Santagostino, 2016, Blood.

Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion.

P. Mannucci, E. Santagostino, P. Mannucci, 2000, Blood.

New findings on inhibitor development: from registries to clinical studies

V. Jiménez‐Yuste, E. Santagostino, M. Makris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Eliminating parvovirus B19 from blood products

M. Morfini, E. Santagostino, A. Azzi, 1994, The Lancet.

High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.

E. Santagostino, P. Mannucci, A. Coppola, 2006, Haematologica.

Comparative pharmacokinetics of rVIII‐SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A

P. Neumeister, C. Leissinger, M. Morfini, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.

P. Mannucci, E. Santagostino, M. Luciani, 2004 .

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

Z. Bentwich, A. Burny, E. Santagostino, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Dental surgery in inherited bleeding disorders with minimal factor support: commentary

E. Santagostino, M. Mancuso, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2020, Pediatric blood & cancer.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting

J. Oldenburg, E. Santagostino, C. Kempton, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

E. Santagostino, M. Mancuso, G. Colombo, 2011, ClinicoEconomics and outcomes research : CEOR.

Ageing successfully with haemophilia: A multidisciplinary programme

E. Santagostino, P. Mannucci, S. Riva, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

E. Santagostino, S. Bernardini, C. Santoro, 2020, Blood transfusion = Trasfusione del sangue.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

E. Santagostino, F. Peyvandi, M. Mancuso, 2019, Haematologica.

Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring

E. Santagostino, C. Biron-Andréani, M. Dischino, 2020, British journal of haematology.

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study

C. Königs, R. Ljung, E. Santagostino, 2020, Haematologica.

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype

M. Margaglione, E. Grandone, F. Torricelli, 2008, Haematologica.

Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study

E. Santagostino, P. Giordano, A. Tagliaferri, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays

E. Santagostino, F. Peyvandi, M. Mancuso, 2013 .

PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

E. Santagostino, 2013, Thrombosis research.

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

V. Jiménez‐Yuste, E. Santagostino, M. Carcao, 2019, Research and practice in thrombosis and haemostasis.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates

E. Santagostino, M. Mancuso, 2017, Journal of clinical medicine.

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

E. Santagostino, H. Ng, S. Lalezari, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

M. Postma, E. Santagostino, J. Nazir, 2020, Advances in Therapy.

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company

A. Iorio, J. Oldenburg, V. Jiménez‐Yuste, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: Non‐interventional, observational study in patients with severe haemophilia A

E. Santagostino, R. Schutgens, K. Meijer, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study

P. Lampertico, E. Santagostino, G. Castaman, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

E. Santagostino, M. Mancuso, 2008, Blood transfusion = Trasfusione del sangue.

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

E. Santagostino, A. Feussner, T. Limsakun, 2014 .

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization

M. Morfini, E. Santagostino, P. Mannucci, 1997 .

Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.

E. Santagostino, C. Négrier, W. Seifert, 2020, Thrombosis research.

Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).

E. Santagostino, 2016, Thrombosis research.

Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis

C. Leissinger, T. Lambert, E. Santagostino, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

V. Jiménez‐Yuste, E. Santagostino, R. Klamroth, 2015, Journal of thrombosis and haemostasis : JTH.

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

C. Hermans, E. Santagostino, G. Di Minno, 2019, Blood.

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

E. Santagostino, S. Lalezari, M. Reding, 2019, Blood.

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

B. Kerlin, E. Santagostino, C. Négrier, 2018, Blood.

Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)

E. Santagostino, F. Driessler, C. Négrier, 2018, Blood.

European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study

V. Jiménez‐Yuste, G. Auerswald, R. Ljung, 2010 .

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.

M. Morfini, E. Santagostino, P. Mannucci, 1997, Transfusion.

Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product

V. Jiménez‐Yuste, E. Santagostino, S. Rangarajan, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Can the genetic profile predict inhibitor development in hemophilia A?

E. Santagostino, 2007, Journal of thrombosis and haemostasis : JTH.

Deep intronic variations may cause mild hemophilia A

E. Santagostino, F. Rodeghiero, G. Castaman, 2011, Journal of thrombosis and haemostasis : JTH.

Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants.

E. Santagostino, P. Mannucci, P. Meroni, 2005, Clinical chemistry.

Immune tolerance induction with moroctocog‐alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high‐titre inhibitors: Data from REF.IT Registry

E. Santagostino, C. Santoro, A. Coppola, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors: A Need for Eradication?

V. Jiménez‐Yuste, E. Santagostino, M. Carcao, 2019, Acta Haematologica.

Comment on "Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies".

E. Santagostino, S. Lethagen, R. Horneff, 2021, Seminars in thrombosis and hemostasis.

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

C. Leissinger, T. Lambert, E. Santagostino, 2015 .

Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients.

P. Mannucci, E. Santagostino, K. Bauer, 1994, Blood.

Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.

E. Santagostino, N. Ciavarella, C. Hay, 1994, Seminars in hematology.

Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B‐LONG trial

E. Santagostino, R. Sidonio, J. Windyga, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

TT virus contaminates first-generation recombinant factor VIII concentrates.

K. Zakrzewska, E. Santagostino, A. Azzi, 2001, Blood.

F8 mRNA studies in haemophilia A patients with different splice site mutations

E. Santagostino, F. Rodeghiero, G. Castaman, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A

J. Astermark, J. Oldenburg, C. Hermans, 2013 .

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies

P. Volkers, R. Ljung, E. Santagostino, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

J. Oldenburg, E. Santagostino, S. Zupančić šalek, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

A. Savic, J. Oldenburg, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Major differences in bleeding symptoms between factor VII deficiency and hemophilia B

G. Mariani, F. Bernardi, E. Santagostino, 2009, Journal of thrombosis and haemostasis : JTH.

Summary report of the First International Conference on inhibitors in haemophilia A.

L. Mantovani, P. Mannucci, F. Rosendaal, 2017, Blood transfusion = Trasfusione del sangue.

Epidemiological data and treatment strategies in children with severe haemophilia in Italy.

M. Biffoni, E. Santagostino, F. Abbonizio, 2020, Annali dell'Istituto superiore di sanita.

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

J. Oldenburg, E. Santagostino, S. Chebon, 2017 .

Modified Factor VIII and Factor IX recombinant products

E. Santagostino, M. Mancuso, 2018, HemaSphere.

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

E. Santagostino, A. Neff, C. Négrier, 2015 .

Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

M. Morfini, E. Santagostino, G. Castaman, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.

A. Savic, E. Santagostino, E. Tuddenham, 2012 .

Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience

P. Mannucci, E. Santagostino, C. Hay, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

E. Santagostino, M. Ozelo, M. Martin-Salces, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls

A. Iorio, A. Nobili, E. Santagostino, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

E. Santagostino, M. Carcao, S. Rangarajan, 2014 .

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2014 .

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2013 .

Handwriting Analysis in Children and Adolescents with Hemophilia: A Pilot Study

M. Mosconi, E. Santagostino, F. Peyvandi, 2020, Journal of clinical medicine.

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting

A. Iorio, J. van der Meer, T. Lambert, 2007, Thrombosis and Haemostasis.

The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A.

M. Morfini, E. Santagostino, G. Di Minno, 2017, Blood transfusion = Trasfusione del sangue.

rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires

J. Astermark, C. Hermans, E. Santagostino, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Gynaecological and obstetrical problems in women with different bleeding disorders

E. Santagostino, A. Federici, F. Peyvandi, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

M. Clerici, E. Santagostino, R. Mazzucchelli, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Desmopressin in moderate hemophilia A patients: a treatment worth considering

J. Voorberg, E. Santagostino, M. Carcao, 2018, Haematologica.

The Outbreak of Hepatitis A in Italian Patients with Hemophilia: Facts and Fancies

P. Mannucci, E. Santagostino, M. Schiavoni, 1994, Vox sanguinis.

Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy.

E. Santagostino, P. Mannucci, M. Colombo, 2002, Blood.

Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population

A. Iorio, E. Santagostino, P. Mannucci, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.

E. Santagostino, F. Abbonizio, A. Giampaolo, 2019, Blood transfusion = Trasfusione del sangue.

Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response

R. Bruno, M. Morfini, E. Santagostino, 2014, Thrombosis and Haemostasis.

Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy

M. Colombo, E. Santagostino, A. Coppola, 2009, Journal of thrombosis and haemostasis : JTH.

Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients

M. Colombo, P. Mannucci, E. Santagostino, 2004, Transfusion.

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

V Chams, A Lachgar, A. Burny, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.

A. Burny, E. Santagostino, P. Mannucci, 1996, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection.

E. Santagostino, A. Gringeri, H. Le Coq, 1995, Cellular and molecular biology.

Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.

E. Santagostino, P. Mannucci, A. Gringeri, 1995, Cellular and molecular biology.

A randomized, placebo-controlled, blind anti-AIDS clinical trial : safety and immunogenicity of a specific anti-IFNα immunization

A. Burny, E. Santagostino, P. Mannucci, 1994 .

Platelets: much more than bricks in a breached wall

E. Santagostino, M. Mancuso, 2017, British journal of haematology.

Prevalence of pancreatic disorders in HIV-infected hemophiliacs: diagnostic methods and their clinical significance.

E. Santagostino, P. Mannucci, A. Gringeri, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy.

M. Morfini, E. Santagostino, P. Mannucci, 2006, Haematologica.

Patterns of Immunogenicity of an Inactivated Hepatitis A Vaccine in Anti-HIV Positive and Negative Hemophilic Patients

A. Zanetti, E. Santagostino, A. Rocino, 1994, Thrombosis and Haemostasis.

Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation

P. Giangrande, E. Santagostino, P. Mannucci, 2000 .

Primary Mantle Cell Lymphoma Cell Cultures Soluble Cd40 Ligand Induces Selective Proliferation of Lymphoma Cells In

P. Giangrande, E. Santagostino, P. Mannucci, 2022 .

Nef Alleles from Human Immunodeficiency Virus Type 1-InfectedLong-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation

E. Santagostino, D. Corti, E. Vicenzi, 2006, Journal of Virology.

Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection.

F. Veglia, E. Santagostino, E. Vicenzi, 1999, Virology.

X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers

E. Santagostino, F. Peyvandi, I. Garagiola, 2020, European Journal of Human Genetics.

Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype

P. Mannucci, E. Santagostino, F. Bertolini, 2009, British journal of haematology.

Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.

A. Lazzarin, A. Mantovani, E. Santagostino, 1997, Blood.

Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia

E. Santagostino, Y. Eguchi, S. Mappa, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Impaired telomerase activity in uninfected haematopoietic progenitors in HIV-1-infected patients.

E. Santagostino, O. Cohen, E. Vicenzi, 1998 .

Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.

E. Santagostino, O. Cohen, E. Vicenzi, 1998 .

Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

R. Bagnall, E. Santagostino, K. Fijnvandraat, 1998, Thrombosis and Haemostasis.

ResearchNef-specific CD 45 RA + CD 8 + T cells secreting MIP-1 β but not IFN-γ are associated with nonprogressive HIV-1 infection

H. Stellbrink, F. Goebel, R. Draenert, 2015 .

Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection

H. Stellbrink, F. Goebel, R. Draenert, 2010, AIDS research and therapy.

The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.

E. Santagostino, P. Mannucci, A. Federici, 2006, Haematologica.

P. Pontisso, M. Morfini, E. Santagostino, 1997, Blood.

559 hemophiliacs infected with the hepatitis C virus Six-month versus 12-month surveillance for hepatocellular carcinoma in

E. Santagostino, A. Rocino, S. Linari, 2013 .

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.

E. Santagostino, P. Mannucci, A. Rocino, 2003, Blood.

C-C chemokines, pivotal in protection against HIV type 1 infection.

S. O’Brien, A. Burny, E. Santagostino, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia

A. Iorio, E. Santagostino, P. Mannucci, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy

A. Burny, E. Santagostino, J. Zagury, 1999 .

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.

A. Burny, E. Santagostino, J. Zagury, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)

E. Santagostino, K. Fischer, J. Mahlangu, 2019, Blood.

expression of the recombinant protein moderately severe factor V deficiency: molecular characterization by Arg2074Cys missense mutation in the C2 domain of factor V causing

E. Santagostino, P. Mannucci, S. Duga, 2013 .

Gene mutations and three‐dimensional structural analysis in 13 families with severe factor X deficiency

P. Mannucci, D. Perry, E. Santagostino, 2002, British journal of haematology.

Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.

A. Lazzarin, E. Santagostino, E. Vicenzi, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Biological effect of active anti-IFN alpha immunization in HIV-infected patients.

A. Burny, E. Santagostino, A. Gringeri, 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Biological effect of active anti-IFNα immunization in HIV-infected patients

A. Burny, E. Santagostino, A. Gringeri, 1995 .

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2012 .

Adverse Effects of Treatment with Porcine Factor VIII

P. Giangrande, E. Santagostino, A. Gringeri, 1991, Thrombosis and Haemostasis.

Factor VIII inhibitors in mild and moderate‐severity haemophilia A

R. Bagnall, E. Santagostino, C. Kessler, 1998, Thrombosis and haemostasis.

Mortality and causes of death in Italian persons with haemophilia, 1990–2007

M. Morfini, E. Santagostino, M. Franchini, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation.

P. Mannucci, P. Giangrande, E. Santagostino, 2000, Blood.

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

J. Esser, G. Tiscia, M. N. D. Minno, 2012, Journal of thrombosis and haemostasis : JTH.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

C. Hermans, E. Santagostino, C. Kessler, 2019 .

Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey

M. Margaglione, M. Morfini, E. Santagostino, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.